Precision Gene Editing Fails in Non-Dividing Cells Like Neurons and Heart Muscle

Precise gene correction via homology-directed repair (HDR) only works in dividing cells. But the cells you most want to fix — brain neurons, heart muscle, skeletal muscle — are non-dividing, so they default to error-prone repair that creates random mutations instead of precise corrections. Prime editing helps but achieves only 1-10% efficiency in vivo.

HDR is restricted to S/G2 cell cycle phases. In post-mitotic cells, HDR rates are <1% while NHEJ dominates at >95%. Base editors make only specific transitions (C>T or A>G). Prime editors achieve 1-10% efficiency in most tissues in vivo. RNA-guided recombinases and site-specific integrases (Bxb1, phiC31) offer alternatives but are early-stage. A 2024 Nature Biotechnology paper showed dual-AAV prime editing in mouse brain, liver, and heart — a significant advance but still at low efficiency.

Why It Matters

Most genetic diseases affecting brain (Huntington's, Rett), heart (HCM, 1 in 500 people), and muscle require correction in non-dividing cells. Without efficient precise correction, gene therapy is limited to 'gene disruption' strategies. This confines CRISPR to approaches like BCL11A knockout for sickle cell.

Startup Approach

Develop compact high-efficiency prime editors using smaller Cas proteins (Cas12f ~1.5 kb vs SpCas9 ~4.1 kb) that fit in single AAV. Or develop site-specific integrases for safe harbor insertion without requiring HDR. The company that solves precision editing in non-dividing cells unlocks the majority of genetic disease indications.

NIH Funding

SCGE Consortium funded HDR improvement in vivo. NHGRI Genome Editing Program. NHLBI funds cardiac gene editing. NINDS funds neuronal gene editing.

Who's Working On It

David Liu lab (Broad, prime editing), Prime Medicine (commercializing PE), Beam Therapeutics (base editing), Omar Abudayyeh & Jonathan Gootenberg (MIT, RNA-guided recombinases), Scribe Therapeutics